The tolerogenic role of IFN-γ

Cytokine and Growth Factor Reviews

Volumn 41, Issue , 2018, Pages 40-53

  Rožman, Primož ^a   Švajger, Urban ^a  

^a BLOOD TRANSFUSION CENTRE OF SLOVENIA   (Slovenia)

Author keywords

autoimmune disease; cancer; graft versus host disease; immunosuppression; Interferon gamma; tolerance

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17;

APLASTIC ANEMIA; BONE MARROW SUPPRESSION; COLITIS; DENDRITIC CELL; EXPERIMENTAL ARTHRITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL MODEL; GRAFT VERSUS HOST REACTION; HOSPITAL; HUMAN; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NEOPLASM; NONHUMAN; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; ADAPTIVE IMMUNITY; ANIMAL; ANTIGEN PRESENTING CELL; CELL DIFFERENTIATION; HELPER CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INNATE IMMUNITY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN-PRESENTING CELLS; CELL DIFFERENTIATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; INTERFERON-GAMMA; INTERLEUKIN-17; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 85045061461     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2018.04.001     Document Type: Review

References (169)

1. Wheelock, E.F., Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin. Science 149:3681 (1965), 310–311.
2. Eberl, G., Colonna, M., Di Santo, J.P., McKenzie, A.N., Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology, Science, 348(6237), 2015, aaa6566.
3. Schroder, K., Hertzog, P.J., Ravasi, T., Hume, D.A., Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:2 (2004), 163–189.
4. Frucht, D.M., Fukao, T., Bogdan, C., Schindler, H., O'Shea, J.J., Koyasu, S., IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol 22:10 (2001), 556–560.
5. Nathan, C.F., Murray, H.W., Wiebe, M.E., Rubin, B.Y., Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 158:3 (1983), 670–689.
6. Young, H.A., Hardy, K.J., Role of interferon-gamma in immune cell regulation. J Leukoc Biol 58:4 (1995), 373–381.
7. Murray, H.W., Spitalny, G.L., Nathan, C.F., Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol 134:3 (1985), 1619–1622.
8. Flynn, J.L., Chan, J., Triebold, K.J., Dalton, D.K., Stewart, T.A., Bloom, B.R., An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178:6 (1993), 2249–2254.
9. Suzuki, Y., Orellana, M.A., Schreiber, R.D., Remington, J.S., Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 240:4851 (1988), 516–518.
10. Dunn, G.P., Koebel, C.M., Schreiber, R.D., Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:11 (2006), 836–884.
11. Steinman, R.M., Hawiger, D., Nussenzweig, M.C., Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003), 685–711.
12. Matzinger, P., The danger model: a renewed sense of self. Science 296:5566 (2002), 301–305.
13. Takenaka, M.C., Quintana, F.J., Tolerogenic dendritic cells. Semin Immunopathol 39:2 (2017), 113–120.
14. Svajger, U., Rozman, P., Tolerogenic dendritic cells: molecular and cellular mechanisms in transplantation. J Leukoc Biol 95:1 (2014), 53–69.
15. Wieckowski, E., Chatta, G.S., Mailliard, R.M., Gooding, W., Palucka, K., Banchereau, J., Kalinski, P., Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes. Prostate 71:2 (2011), 125–133.
16. Vieira, P.L., de Jong, E.C., Wierenga, E.A., Kapsenberg, M.L., Kalinski, P., Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 164:9 (2000), 4507–4512.
17. Munn, D.H., Sharma, M.D., Baban, B., Harding, H.P., Zhang, Y., Ron, D., Mellor, A.L., GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22:5 (2005), 633–642.
18. Cobbold, S.P., Adams, E., Farquhar, C.A., Nolan, K.F., Howie, D., Lui, K.O., Fairchild, P.J., Mellor, A.L., Ron, D., Waldmann, H., Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A 106:29 (2009), 12055–12060.
19. Munn, D.H., Mellor, A.L., Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34:3 (2013), 137–143.
20. Jurgens, B., Hainz, U., Fuchs, D., Felzmann, T., Heitger, A., Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 114:15 (2009), 3235–3243.
21. Li, Q., Harden, J.L., Anderson, C.D., Egilmez, N.K., Tolerogenic Phenotype of IFN-gamma-Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO-Kynurenine/AhR-IDO Loop. J Immunol 197:3 (2016), 962–970.
22. Nguyen, N.T., Kimura, A., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii-Kuriyama, Y., Kishimoto, T., Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A 107:46 (2010), 19961–19966.
23. Xiao, B.G., Wu, X.C., Yang, J.S., Xu, L.Y., Liu, X., Huang, Y.M., Bjelke, B., Link, H., Therapeutic potential of IFN-gamma-modified dendritic cells in acute and chronic experimental allergic encephalomyelitis. Int Immunol 16:1 (2004), 13–22.
24. Svajger, U., Obermajer, N., Jeras, M., IFN-gamma-rich environment programs dendritic cells toward silencing of cytotoxic immune responses. J Leukoc Biol 95:1 (2014), 33–46.
25. Contini, P., Ghio, M., Poggi, A., Filaci, G., Indiveri, F., Ferrone, S., Puppo, F., Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 33:1 (2003), 125–134.
26. Vignali, D.A., Collison, L.W., Workman, C.J., How regulatory T cells work. Nat Rev Immunol 8:7 (2008), 523–532.
27. Koch, M.A., Tucker-Heard, G., Perdue, N.R., Killebrew, J.R., Urdahl, K.B., Campbell, D.J., The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 10:6 (2009), 595–602.
28. Liston, A., Gray, D.H., Homeostatic control of regulatory T cell diversity. Nat Rev Immunol 14:3 (2014), 154–165.
29. Zheng, J., Liu, Y., Qin, G., Lam, K.T., Guan, J., Xiang, Z., Lewis, D.B., Lau, Y.L., Tu, W., Generation of human Th1-like regulatory CD4+ T cells by an intrinsic IFN-gamma- and T-bet-dependent pathway. Eur J Immunol 41:1 (2011), 128–139.
30. Feng, G., Gao, W., Strom, T.B., Oukka, M., Francis, R.S., Wood, K.J., Bushell, A., Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur J Immunol 38:9 (2008), 2512–2527.
31. Komatsu, N., Okamoto, K., Sawa, S., Nakashima, T., Oh-hora, M., Kodama, T., Tanaka, S., Bluestone, J.A., Takayanagi, H., Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 20:1 (2014), 62–68.
32. Takahashi, R., Nishimoto, S., Muto, G., Sekiya, T., Tamiya, T., Kimura, A., Morita, R., Asakawa, M., Chinen, T., Yoshimura, A., SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-{gamma} and IL-17A production. J Exp Med 208:10 (2011), 2055–2067.
33. Sawitzki, B., Kingsley, C.I., Oliveira, V., Karim, M., Herber, M., Wood, K.J., IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 201:12 (2005), 1925–1935.
34. Daniel, V., Naujokat, C., Sadeghi, M., Weimer, R., Renner, F., Yildiz, S., Opelz, G., Observational support for an immunoregulatory role of CD3+CD4+CD25+IFN-gamma+ blood lymphocytes in kidney transplant recipients with good long-term graft outcome. Transpl Int 21:7 (2008), 646–660.
35. Jiang, X.F., Zhu, L., Cui, Z.M., Guo, D.W., Sun, W.Y., Lin, L., Tang, Y.F., Wang, X.F., Liang, J., Transplant long-surviving induced by CD40-CD40 ligand costimulation blockade is dependent on IFN-gamma through its effect on CD4(+)CD25(+) regulatory T cells. Transpl Immunol 24:2 (2011), 113–118.
36. Koenecke, C., Lee, C.W., Thamm, K., Fohse, L., Schafferus, M., Mittrucker, H.W., Floess, S., Huehn, J., Ganser, A., Forster, R., Prinz, I., IFN-gamma production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease. J Immunol 189:6 (2012), 2890–2896.
37. Naves, R., Singh, S.P., Cashman, K.S., Rowse, A.L., Axtell, R.C., Steinman, L., Mountz, J.D., Steele, C., De Sarno, P., Raman, C., The interdependent, overlapping, and differential roles of type I and II IFNs in the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 191:6 (2013), 2967–2977.
38. Tanuma, N., Shin, T., Kogure, K., Matsumoto, Y., Differential role of TNF-alpha and IFN-gamma in the brain of rats with chronic relapsing autoimmune encephalomyelitis. J Neuroimmunol 96:1 (1999), 73–79.
39. Furlan, R., Brambilla, E., Ruffini, F., Poliani, P.L., Bergami, A., Marconi, P.C., Franciotta, D.M., Penna, G., Comi, G., Adorini, L., Martino, G., Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 167:3 (2001), 1821–1829.
40. Olsson, T., Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J Neuroimmunol 40:2-3 (1992), 211–218.
41. Fletcher, J.M., Lalor, S.J., Sweeney, C.M., Tubridy, N., Mills, K.H., T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162:1 (2010), 1–11.
42. Aranami, T., Yamamura, T., Th17 Cells and autoimmune encephalomyelitis (EAE/MS),. Allergol Int 57:2 (2008), 115–120.
43. Noack, M., Miossec, P., Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 13:6 (2014), 668–677.
44. Berghmans, N., Nuyts, A., Uyttenhove, C., Van Snick, J., Opdenakker, G., Heremans, H., Interferon-gamma orchestrates the number and function of Th17 cells in experimental autoimmune encephalomyelitis. J Interferon Cytokine Res 31:7 (2011), 575–587.
45. Billiau, A., Heremans, H., Vandekerckhove, F., Dijkmans, R., Sobis, H., Meulepas, E., Carton, H., Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 140:5 (1988), 1506–1510.
46. Heremans, H., Dillen, C., Groenen, M., Martens, E., Billiau, A., Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-gamma. Eur J Immunol 26:10 (1996), 2393–2398.
47. Rajaiah, R., Puttabyatappa, M., Polumuri, S.K., Moudgil, K.D., Interleukin-27 and interferon-gamma are involved in regulation of autoimmune arthritis. J Biol Chem 286:4 (2011), 2817–2825.
48. Murugaiyan, G., Mittal, A., Weiner, H.L., Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci U S A 107:25 (2010), 11495–11500.
49. Chong, W.P., van Panhuys, N., Chen, J., Silver, P.B., Jittayasothorn, Y., Mattapallil, M.J., Germain, R.N., Caspi, R.R., NK-DC crosstalk controls the autopathogenic Th17 response through an innate IFN-gamma-IL-27 axis. J Exp Med 212:10 (2015), 1739–1752.
50. Kaplan, M.H., Th9 cells: differentiation and disease. Immunol Rev 252:1 (2013), 104–115.
51. Elyaman, W., Khoury, S.J., Th9 cells in the pathogenesis of EAE and multiple sclerosis. Semin Immunopathol 39:1 (2017), 79–87.
52. Murugaiyan, G., Beynon, V., Pires Da Cunha, A., Joller, N., Weiner, H.L., IFN-gamma limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J Immunol 189:11 (2012), 5277–5283.
53. Vermeire, K., Heremans, H., Vandeputte, M., Huang, S., Billiau, A., Matthys, P., Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 158:11 (1997), 5507–5513.
54. Kelchtermans, H., De Klerck, B., Mitera, T., Van Balen, M., Bullens, D., Billiau, A., Leclercq, G., Matthys, P., Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res Ther 7:2 (2005), R402–R415.
55. De Klerck, B., Carpentier, I., Lories, R.J., Habraken, Y., Piette, J., Carmeliet, G., Beyaert, R., Billiau, A., Matthys, P., Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b+ myelopoiesis. Arthritis Res Ther 6:3 (2004), R220–R231.
56. Kelchtermans, H., Struyf, S., De Klerck, B., Mitera, T., Alen, M., Geboes, L., Van Balen, M., Dillen, C., Put, W., Gysemans, C., Billiau, A., Van Damme, J., Matthys, P., Protective role of IFN-γ in collagen-induced arthritis conferred by inhibition of mycobacteria-induced granulocyte chemotactic protein-2 production. Journal of Leukocyte Biology 81:4 (2007), 1044–1053.
57. Kageyama, Y., Koide, Y., Yoshida, A., Uchijima, M., Arai, T., Miyamoto, S., Ozeki, T., Hiyoshi, M., Kushida, K., Inoue, T., Reduced susceptibility to collagen-induced arthritis in mice deficient in IFN-gamma receptor. J Immunol 161:3 (1998), 1542–1548.
58. Kim, E.Y., Chi, H.H., Bouziane, M., Gaur, A., Moudgil, K.D., Regulation of autoimmune arthritis by the pro-inflammatory cytokine interferon-gamma. Clin Immunol 127:1 (2008), 98–106.
59. Satpute, S.R., Rajaiah, R., Polumuri, S.K., Moudgil, K.D., Tolerization with Hsp65 induces protection against adjuvant-induced arthritis by modulating the antigen-directed interferon-gamma, interleukin-17, and antibody responses. Arthritis Rheum 60:1 (2009), 103–113.
60. Chabaud, M., Durand, J.M., Buchs, N., Fossiez, F., Page, G., Frappart, L., Miossec, P., Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42:5 (1999), 963–970.
61. Raza, K., Scheel-Toellner, D., Lee, C.Y., Pilling, D., Curnow, S.J., Falciani, F., Trevino, V., Kumar, K., Assi, L.K., Lord, J.M., Gordon, C., Buckley, C.D., Salmon, M., Synovial fluid leukocyte apoptosis is inhibited in patients with very early rheumatoid arthritis. Arthritis Res Ther, 8(4), 2006, R120.
62. Nakae, S., Nambu, A., Sudo, K., Iwakura, Y., Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171:11 (2003), 6173–6177.
63. Kolls, J.K., Linden, A., Interleukin-17 family members and inflammation. Immunity 21:4 (2004), 467–476.
64. Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, K.M., Weaver, C.T., Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6:11 (2005), 1123–1132.
65. Park, H., Li, Z., Yang, X.O., Chang, S.H., Nurieva, R., Wang, Y.H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., Dong, C., A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:11 (2005), 1133–1141.
66. Kelchtermans, H., Schurgers, E., Geboes, L., Mitera, T., Van Damme, J., Van Snick, J., Uyttenhove, C., Matthys, P., Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res Ther, 11(4), 2009, R122.
67. Sarkar, S., Zhou, X., Justa, S., Bommireddy, S.R., Interleukin-22 reduces the severity of collagen-induced arthritis in association with increased levels of interleukin-10. Arthritis Rheum 65:4 (2013), 960–971.
68. Obermeier, F., Kojouharoff, G., Hans, W., Scholmerich, J., Gross, V., Falk, W., Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 116:2 (1999), 238–245.
69. Ito, R., Shin-Ya, M., Kishida, T., Urano, A., Takada, R., Sakagami, J., Imanishi, J., Kita, M., Ueda, Y., Iwakura, Y., Kataoka, K., Okanoue, T., Mazda, O., Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol 146:2 (2006), 330–338.
70. Singh, U.P., Singh, S., Taub, D.D., Lillard, J.W. Jr., Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice,. J Immunol 171:3 (2003), 1401–1406.
71. Singh, U.P., Singh, S., Iqbal, N., Weaver, C.T., McGhee, J.R., Lillard, J.W. Jr., IFN-gamma-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res 23:10 (2003), 591–600.
72. Harbour, S.N., Maynard, C.L., Zindl, C.L., Schoeb, T.R., Weaver, C.T., Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proceedings of the National Academy of Sciences 112:22 (2015), 7061–7066.
73. Kamada, N., Hisamatsu, T., Okamoto, S., Chinen, H., Kobayashi, T., Sato, T., Sakuraba, A., Kitazume, M.T., Sugita, A., Koganei, K., Akagawa, K.S., Hibi, T., Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 118:6 (2008), 2269–2280.
74. Davidson, N.J., Hudak, S.A., Lesley, R.E., Menon, S., Leach, M.W., Rennick, D.M., IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 161:6 (1998), 3143–3149.
75. Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., McKenzie, B., Kleinschek, M.A., Owyang, A., Mattson, J., Blumenschein, W., Murphy, E., Sathe, M., Cua, D.J., Kastelein, R.A., Rennick, D., IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116:5 (2006), 1310–1316.
76. Cho, J.H., The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 8:6 (2008), 458–466.
77. Sheikh, S.Z., Matsuoka, K., Kobayashi, T., Li, F., Rubinas, T., Plevy, S.E., Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. J Immunol 184:8 (2010), 4069–4073.
78. Cerovic, V., Bain, C.C., Mowat, A.M., Milling, S.W., Intestinal macrophages and dendritic cells: what's the difference?. Trends Immunol 35:6 (2014), 270–277.
79. Muzaki, A.R., Tetlak, P., Sheng, J., Loh, S.C., Setiagani, Y.A., Poidinger, M., Zolezzi, F., Karjalainen, K., Ruedl, C., Intestinal CD103(+)CD11b(-) dendritic cells restrain colitis via IFN-gamma-induced anti-inflammatory response in epithelial cells. Mucosal Immunol 9:2 (2016), 336–351.
80. Siegmund, B., Fantuzzi, G., Rieder, F., Gamboni-Robertson, F., Lehr, H.A., Hartmann, G., Dinarello, C.A., Endres, S., Eigler, A., Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 281:4 (2001), R1264–R1273.
81. Thelemann, C., Eren, R.O., Coutaz, M., Brasseit, J., Bouzourene, H., Rosa, M., Duval, A., Lavanchy, C., Mack, V., Mueller, C., Reith, W., Acha-Orbea, H., Interferon-gamma induces expression of MHC class II on intestinal epithelial cells and protects mice from colitis. PLoS One, 9(1), 2014, e86844.
82. Kambayashi, T., Laufer, T.M., Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell?. Nat Rev Immunol 14:11 (2014), 719–730.
83. Jagasia, M., Arora, M., Flowers, M.E., Chao, N.J., McCarthy, P.L., Cutler, C.S., Urbano-Ispizua, A., Pavletic, S.Z., Haagenson, M.D., Zhang, M.J., Antin, J.H., Bolwell, B.J., Bredeson, C., Cahn, J.Y., Cairo, M., Gale, R.P., Gupta, V., Lee, S.J., Litzow, M., Weisdorf, D.J., Horowitz, M.M., Hahn, T., Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119:1 (2012), 296–307.
84. Sung, A.D., Chao, N.J., Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment. Stem Cells Transl Med 2:1 (2013), 25–32.
85. Shlomchik, W.D., Couzens, M.S., Tang, C.B., McNiff, J., Robert, M.E., Liu, J., Shlomchik, M.J., Emerson, S.G., Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285:5426 (1999), 412–415.
86. Matte, C.C., Liu, J., Cormier, J., Anderson, B.E., Athanasiadis, I., Jain, D., McNiff, J., Shlomchik, W.D., Donor APCs are required for maximal GVHD but not for GVL. Nat Med 10:9 (2004), 987–992.
87. Lu, Y., Waller, E.K., Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant 15:11 (2009), 1347–1353.
88. Ghimire, S., Weber, D., Mavin, E., Wang, X.N., Dickinson, A.M., Holler, E., Pathophysiology of GvHD and Other HSCT-Related Major Complications. Front Immunol, 8, 2017, 79.
89. Hill, G.R., Ferrara, J.L., The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95:9 (2000), 2754–2759.
90. Snijders, A., Kalinski, P., Hilkens, C.M., Kapsenberg, M.L., High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10:11 (1998), 1593–1598.
91. Wang, H., Yang, Y.G., The complex and central role of interferon-gamma in graft-versus-host disease and graft-versus-tumor activity. Immunol Rev 258:1 (2014), 30–44.
92. Shlomchik, W.D., Lee, S.J., Couriel, D., Pavletic, S.Z., Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant 13:Suppl. 1 (2007), 2–10.
93. Coghill, J.M., Sarantopoulos, S., Moran, T.P., Murphy, W.J., Blazar, B.R., Serody, J.S., Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 117:12 (2011), 3268–3276.
94. Lamarthee, B., Malard, F., Gamonet, C., Bossard, C., Couturier, M., Renauld, J.C., Mohty, M., Saas, P., Gaugler, B., Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10. Mucosal Immunol 9:2 (2016), 309–321.
95. MacDonald, K.P., Hill, G.R., Blazar, B.R., Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 129:1 (2017), 13–21.
96. Nava, P., Koch, S., Laukoetter, M.G., Lee, W.Y., Kolegraff, K., Capaldo, C.T., Beeman, N., Addis, C., Gerner-Smidt, K., Neumaier, I., Skerra, A., Li, L., Parkos, C.A., Nusrat, A., Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. Immunity 32:3 (2010), 392–402.
97. Ellison, C.A., Natuik, S.A., McIntosh, A.R., Scully, S.A., Danilenko, D.M., Gartner, J.G., The role of interferon-gamma, nitric oxide and lipopolysaccharide in intestinal graft-versus-host disease developing in F1-hybrid mice. Immunology 109:3 (2003), 440–449.
98. Wei, B., Baker, S., Wieckiewicz, J., Wood, K.J., IFN-gamma triggered STAT1-PKB/AKT signalling pathway influences the function of alloantigen reactive regulatory T cells. Am J Transplant 10:1 (2010), 69–80.
99. Lu, Y., Giver, C.R., Sharma, A., Li, J.M., Darlak, K.A., Owens, L.M., Roback, J.D., Galipeau, J., Waller, E.K., IFN-gamma and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood 119:4 (2012), 1075–1085.
100. Kaminski, E., Hows, J., Man, S., Brookes, P., Mackinnon, S., Hughes, T., Avakian, O., Goldman, J.M., Batchelor, J.R., Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation 48:4 (1989), 608–613.
101. Valujskikh, A., Lantz, O., Celli, S., Matzinger, P., Heeger, P.S., Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol 3:9 (2002), 844–851.
102. Asavaroengchai, W., Wang, H., Wang, S., Wang, L., Bronson, R., Sykes, M., Yang, Y.G., An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 13:1 (2007), 46–55.
103. Hill, M., Thebault, P., Segovia, M., Louvet, C., Beriou, G., Tilly, G., Merieau, E., Anegon, I., Chiffoleau, E., Cuturi, M.C., Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferon-gamma and epstein-barr virus-induced gene 3. Am J Transplant 11:10 (2011), 2036–2045.
104. Yang, Y.G., Qi, J., Wang, M.G., Sykes, M., Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood 99:11 (2002), 4207–4215.
105. Chu, C.Q., Wittmer, S., Dalton, D.K., Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med 192:1 (2000), 123–128.
106. Dalton, D.K., Haynes, L., Chu, C.Q., Swain, S.L., Wittmer, S., Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med 192:1 (2000), 117–122.
107. Badovinac, V.P., Tvinnereim, A.R., Harty, J.T., Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 290:5495 (2000), 1354–1358.
108. Novelli, F., D'Elios, M.M., Bernabei, P., Ozmen, L., Rigamonti, L., Almerigogna, F., Forni, G., Del Prete, G., Expression and role in apoptosis of the alpha- and beta-chains of the IFN-gamma receptor on human Th1 and Th2 clones. J Immunol 159:1 (1997), 206–213.
109. Refaeli, Y., Parijs, L. Van, Alexander, S.I., Abbas, A.K., Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 196:7 (2002), 999–1005.
110. Konieczny, B.T., Dai, Z., Elwood, E.T., Saleem, S., Linsley, P.S., Baddoura, F.K., Larsen, C.P., Pearson, T.C., Lakkis, F.G., IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol 160:5 (1998), 2059–2064.
111. Keir, M.E., Liang, S.C., Guleria, I., Latchman, Y.E., Qipo, A., Albacker, L.A., Koulmanda, M., Freeman, G.J., Sayegh, M.H., Sharpe, A.H., Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203:4 (2006), 883–895.
112. Schoop, R., Wahl, P., Le Hir, M., Heemann, U., Wang, M., Wuthrich, R.P., Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol Dial Transplant 19:11 (2004), 2713–2720.
113. Yi, T., Chen, Y., Wang, L., Du, G., Huang, D., Zhao, D., Johnston, H., Young, J., Todorov, I., Umetsu, D.T., Chen, L., Iwakura, Y., Kandeel, F., Forman, S., Zeng, D., Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 114:14 (2009), 3101–3112.
114. Blazar, B.R., Carreno, B.M., Panoskaltsis-Mortari, A., Carter, L., Iwai, Y., Yagita, H., Nishimura, H., Taylor, P.A., Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 171:3 (2003), 1272–1277.
115. Hommes, D.W., Mikhajlova, T.L., Stoinov, S., Stimac, D., Vucelic, B., Lonovics, J., Zakuciova, M., D'Haens, G., Van Assche, G., Ba, S., Lee, S., Pearce, T., Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55:8 (2006), 1131–1137.
116. Reinisch, W., Hommes, D.W., Van Assche, G., Colombel, J.F., Gendre, J.P., Oldenburg, B., Teml, A., Geboes, K., Ding, H., Zhang, L., Tang, M., Cheng, M., van Deventer, S.J., Rutgeerts, P., Pearce, T., A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 55:8 (2006), 1138–1144.
117. Sigidin, Y.A., Loukina, G.V., Skurkovich, B., Skurkovich, S., Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 30:4 (2001), 203–207.
118. Jang, I.G., Yang, J.K., Lee, H.J., Yi, J.Y., Kim, H.O., Kim, C.W., Kim, T.Y., Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 42:6 (2000), 1033–1040.
119. Machold, K.P., Neumann, K., Smolen, J.S., Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study. Ann Rheum Dis 51:9 (1992), 1039–1043.
120. Hofschneider, P.H., Winter, U., Lemmel, E.-M., Brölz, B., Gaus, W., Schmid, S., Obert, H.-J., Stetter, C., Auer, I.O., Papst, C., Boesken, W.H., Stierle, H.E., Botzenhardt, U., Reemtsen, W., Brackertz, D., Richter, D., Diehl, V., von Kalle, A.K., Gärtner, C., Herzig, S., Goronzy, J., Weyand, C., Kalden, J.R., Strobel, F., Machalke, K., Peter, H.H., Meske, S., Schattenkirchner, M., Krüger, K., Sprekeler, R., Waller, H.D., Saal, J.G., Warnatz, H., Lemm, G., Wilms, K., Stolzenburg, T., Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis. Rheumatology International 12:5 (1992), 175–185.
121. Lemmel, E.M., Brackertz, D., Franke, M., Gaus, W., Hartl, P.W., Machalke, K., Mielke, H., Obert, H.J., Peter, H.H., Sieper, J., et al. Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int 8:2 (1988), 87–93.
122. Leipe, J., Grunke, M., Dechant, C., Reindl, C., Kerzendorf, U., Schulze-Koops, H., Skapenko, A., Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 62:10 (2010), 2876–2885.
123. Pope, R.M., Shahrara, S., Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat Rev Rheumatol 9:4 (2013), 252–256.
124. Tsuchiya, A., Yano, M., Tocharus, J., Kojima, H., Fukumoto, M., Kawaichi, M., Oka, C., Expression of mouse HtrA1 serine protease in normal bone and cartilage and its upregulation in joint cartilage damaged by experimental arthritis. Bone 37:3 (2005), 323–336.
125. Polur, I., Lee, P.L., Servais, J.M., Xu, L., Li, Y., Role of HTRA1, a serine protease, in the progression of articular cartilage degeneration. Histol Histopathol 25:5 (2010), 599–608.
126. Grau, S., Richards, P.J., Kerr, B., Hughes, C., Caterson, B., Williams, A.S., Junker, U., Jones, S.A., Clausen, T., Ehrmann, M., The role of human HtrA1 in arthritic disease. J Biol Chem 281:10 (2006), 6124–6129.
127. Hu, S.I., Carozza, M., Klein, M., Nantermet, P., Luk, D., Crowl, R.M., Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem 273:51 (1998), 34406–34412.
128. Hou, Y., Lin, H., Zhu, L., Liu, Z., Hu, F., Shi, J., Yang, T., Shi, X., Guo, H., Tan, X., Zhang, L., Wang, Q., Li, Z., Zhao, Y., The inhibitory effect of IFN-gamma on protease HTRA1 expression in rheumatoid arthritis. J Immunol 193:1 (2014), 130–138.
129. Wright, H.L., Thomas, H.B., Moots, R.J., Edwards, S.W., Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. Rheumatology (Oxford) 54:1 (2015), 188–193.
130. Panitch, H.S., Hirsch, R.L., Haley, A.S., Johnson, K.P., Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1:8538 (1987), 893–895.
131. Miller, N.M., Wang, J., Tan, Y., Dittel, B.N., Anti-inflammatory mechanisms of IFN-gamma studied in experimental autoimmune encephalomyelitis reveal neutrophils as a potential target in multiple sclerosis. Front Neurosci, 9, 2015, 287.
132. Bever, C.T. Jr., Panitch, H.S., Levy, H.B., McFarlin, D.E., Johnson, K.P., Gamma-interferon induction in patients with chronic progressive MS. Neurology 41:7 (1991), 1124–1127.
133. Jagessar, S.A., Gran, B., Heijmans, N., Bauer, J., Laman, J.D., t Hart, B.A., Constantinescu, C.S., Discrepant effects of human interferon-gamma on clinical and immunological disease parameters in a novel marmoset model for multiple sclerosis. J Neuroimmune Pharmacol 7:1 (2012), 253–265.
134. Young, N.S., Calado, R.T., Scheinberg, P., Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108:8 (2006), 2509–2519.
135. Kordasti, S., Marsh, J., Al-Khan, S., Jiang, J., Smith, A., Mohamedali, A., Abellan, P.P., Veen, C., Costantini, B., Kulasekararaj, A.G., Benson-Quarm, N., Seidl, T., Mian, S.A., Farzaneh, F., Mufti, G.J., Functional characterization of CD4+ T cells in aplastic anemia. Blood 119:9 (2012), 2033–2043.
136. Shi, J., Ge, M., Lu, S., Li, X., Shao, Y., Huang, J., Huang, Z., Zhang, J., Nie, N., Zheng, Y., Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia. Blood 120:8 (2012), 1624–1632.
137. Frickhofen, N., Heimpel, H., Kaltwasser, J.P., Schrezenmeier, H., German, G., Aplastic Anemia Study, Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101:4 (2003), 1236–1242.
138. Maciejewski, J., Selleri, C., Anderson, S., Young, N.S., Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85:11 (1995), 3183–3190.
139. Klimpel, G.R., Fleischmann, W.R. Jr., Klimpel, K.D., Gamma interferon (IFN gamma) and IFN alpha/beta suppress murine myeloid colony formation (CFU-C)N: magnitude of suppression is dependent upon level of colony-stimulating factor (CSF). J Immunol 129:1 (1982), 76–80.
140. Zoumbos, N.C., Djeu, J.Y., Young, N.S., Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol 133:2 (1984), 769–774.
141. Snoeck, H.W., Van Bockstaele, D.R., Nys, G., Lenjou, M., Lardon, F., Haenen, L., Rodrigus, I., Peetermans, M.E., Berneman, Z.N., Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells. J Exp Med 180:3 (1994), 1177–1182.
142. Selleri, C., Maciejewski, J.P., Sato, T., Young, N.S., Interferon-gamma constitutively expressed in the stromal microenvironment of human marrow cultures mediates potent hematopoietic inhibition. Blood 87:10 (1996), 4149–4157.
143. de Bruin, A.M., Voermans, C., Nolte, M.A., Impact of interferon-gamma on hematopoiesis. Blood 124:16 (2014), 2479–2486.
144. Li, J., Zhao, Q., Xing, W., Feng, J., Wu, H., Li, H., Ge, M., Tian, K., Li, X., Zhou, J., Liu, B., Zhang, L., Zheng, Y., Han, Z.C., Interleukin-27 enhances the production of tumour necrosis factor-alpha and interferon-gamma by bone marrow T lymphocytes in aplastic anaemia. Br J Haematol 153:6 (2011), 764–772.
145. Du, H.Z., Wang, Q., Ji, J., Shen, B.M., Wei, S.C., Liu, L.J., Ding, J., Ma, D.X., Wang, W., Peng, J., Hou, M., Expression of IL-27, Th1 and Th17 in patients with aplastic anemia. J Clin Immunol 33:2 (2013), 436–445.
146. Silva-Santos, B., Serre, K., Norell, H., gammadelta T cells in cancer. Nat Rev Immunol 15:11 (2015), 683–691.
147. Morvan, M.G., Lanier, L.L., NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 16:1 (2016), 7–19.
148. Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., Brossay, L., Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12:4 (2012), 239–252.
149. Glasner, A., Levi, A., Enk, J., Isaacson, B., Viukov, S., Orlanski, S., Scope, A., Neuman, T., Enk, C.D., Hanna, J.H., Sexl, V., Jonjic, S., Seliger, B., Zitvogel, L., Mandelboim, O., NKp46 Receptor-Mediated Interferon-gamma Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity 48:1 (2018), 107–119 e4.
150. Zaidi, M.R., Merlino, G., The two faces of interferon-gamma in cancer. Clin Cancer Res 17:19 (2011), 6118–6124.
151. Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., Mandai, M., IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 112:9 (2015), 1501–1509.
152. Chen, L., Han, X., Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125:9 (2015), 3384–3391.
153. Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D.R., Albright, A., Cheng, J.D., Kang, S.P., Shankaran, V., Piha-Paul, S.A., Yearley, J., Seiwert, T.Y., Ribas, A., McClanahan, T.K., IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:8 (2017), 2930–2940.
154. Zhang, X., Zeng, Y., Qu, Q., Zhu, J., Liu, Z., Ning, W., Zeng, H., Zhang, N., Du, W., Chen, C., Huang, J.A., PD-L1 induced by IFN-gamma from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol 22:6 (2017), 1026–1033.
155. Platten, M., Wick, W., Van den Eynde, B.J., Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 72:21 (2012), 5435–5440.
156. Sikalidis, A.K., Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer?. Pathol Oncol Res 21:1 (2015), 9–17.
157. Sosa, M.S., Bragado, P., Aguirre-Ghiso, J.A., Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 14:9 (2014), 611–622.
158. Liu, Y., Liang, X., Yin, X., Lv, J., Tang, K., Ma, J., Ji, T., Zhang, H., Dong, W., Jin, X., Chen, D., Li, Y., Zhang, S., Xie, H.Q., Zhao, B., Zhao, T., Lu, J., Hu, Z.-W., Cao, X., Qin, F.X.-F., Huang, B., Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells. Nature Communications, 8, 2017, 15207.
159. Rouas-Freiss, N., Moreau, P., Menier, C., Carosella, E.D., HLA-G in cancer: a way to turn off the immune system. Seminars in Cancer Biology 13:5 (2003), 325–336.
160. de Kruijf, E.M., Sajet, A., van Nes, J.G., Natanov, R., Putter, H., Smit, V.T., Liefers, G.J., van den Elsen, P.J., van de Velde, C.J., Kuppen, P.J., HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 185:12 (2010), 7452–7459.
161. LeMaoult, J., Krawice-Radanne, I., Dausset, J., Carosella, E.D., HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci U S A 101:18 (2004), 7064–7069.
162. Le Friec, G., Laupeze, B., Fardel, O., Sebti, Y., Pangault, C., Guilloux, V., Beauplet, A., Fauchet, R., Amiot, L., Soluble HLA-G inhibits human dendritic cell-triggered allogeneic T-cell proliferation without altering dendritic differentiation and maturation processes. Hum Immunol 64:8 (2003), 752–761.
163. Loumagne, L., Baudhuin, J., Favier, B., Montespan, F., Carosella, E.D., Rouas-Freiss, N., In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance. Int J Cancer 135:9 (2014), 2107–2117.
164. Ristich, V., Liang, S., Zhang, W., Wu, J., Horuzsko, A., Tolerization of dendritic cells by HLA-G. Eur J Immunol 35:4 (2005), 1133–1142.
165. Sun, Z., Wang, S., Zhao, R.C., The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J Hematol Oncol, 7, 2014, 14.
166. Liotta, F., Querci, V., Mannelli, G., Santarlasci, V., Maggi, L., Capone, M., Rossi, M.C., Mazzoni, A., Cosmi, L., Romagnani, S., Maggi, E., Gallo, O., Annunziato, F., Mesenchymal stem cells are enriched in head neck squamous cell carcinoma, correlates with tumour size and inhibit T-cell proliferation. Br J Cancer 112:4 (2015), 745–754.
167. Ling, W., Zhang, J., Yuan, Z., Ren, G., Zhang, L., Chen, X., Rabson, A.B., Roberts, A.I., Wang, Y., Shi, Y., Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res 74:5 (2014), 1576–1587.
168. Huang, B., Pan, P.Y., Li, Q., Sato, A.I., Levy, D.E., Bromberg, J., Divino, C.M., Chen, S.H., Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:2 (2006), 1123–1131.
169. Medina-Echeverz, J., Haile, L.A., Zhao, F., Gamrekelashvili, J., Ma, C., Metais, J.Y., Dunbar, C.E., Kapoor, V., Manns, M.P., Korangy, F., Greten, T.F., IFN-gamma regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1. Eur J Immunol 44:8 (2014), 2457–2467.